Menu

Home / For Visitors / 2026 Exhibitor Product / （1）BY-101 （2）BY-102 （3）BY-103

（1）BY-101 （2）BY-102 （3）BY-103

Model: （1）BY-101 （2）BY-102 （3）BY-103

Category: Pharmaceutical

Exhibitor: BOYEN THERAPEUTICS, INC.

Booth No: L222

Characteristic

BoYen has a platform that creates patentable new drug candidates. Currently, 3 candidates are under development. BY-101 is an USFDA designated orphan drug with a 7-year marketing exclusivity; the phase 2 candidate is intended for the treatment of acute myeloid leukemia (AML). BY-102 is a patented drug candidate for the treatment of multiple sclerosis and other immune related diseases. BY-103 is a patented drug candidate for oral combination treatment of AML. Its phase 1 trial begins this fall.

Products you may be interested in

Highest Rated Products

TOP